[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genital-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genital-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100367261","research-project-on-reminders-and-self-sampling-can-increase-participation-in-gynecology-cell-sampling---preventive-examination-against-cervical-cancer-100367261",false,"NCT04061967","Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.","Inclusion Criteria:\n\n* Women resident in Region Skane who either: 1) have had glandular cell transformation that has not been followed-up, 2) are older than 65 years and have had cell transformation that has not been followed-up or who have not participated in screening during the last 10 years, 3) women who have not been screened for more than 15 years.\n\nExclusion Criteria:\n\n* No exclusion except those who do not consent.","FEMALE","33 Years","75 Years",{"count":19,"type":20},20000,"ESTIMATED","INTERVENTIONAL",[23],"NA","Prevention of cervical cancer with cervical screening is one of the most successful screening activities in medicine. In Sweden, screening was implemented in the 1960s and has since prevented tens of thousands of women from having cervical cancer. Individual invitations to screening result in increased attendance therefore evaluating strategies for reaching women through invitations is particularly valuable. Women who regularly attend screening following an invitation reduce their risk of cervical cancer by as much as 90%. Of the women who are diagnosed with cervical cancer (about 550 women per year in Sweden), as many as 38% did not participate in the screening. Invitations for screening are sent to the entire population in Sweden aged 23-70. The current coverage of screening is 82.9%, which represents the proportion of women ages 23-70 who attend according to recommendations. In addition, many women are sporadic attenders who reduce their risk for cancer somewhat. The highest cancer risk is seen among those women who have never participated as well as women who have had a history of precancerous lesions or HPV infection but have not been followed-up. Cervical cancer is the first form of cancer for which there are approved molecular screening tests (HPV test). Unlike the older screening method (cytology), self-collected samples can be analyzed for HPV (the analysis method is so sensitive that it does not matter if the sample is not optimally taken).\n\nInvitations and reminders about cervical screening are sent by letter to the woman's home address (about 3 million letters per year in Sweden). This strategy results in a waste of resources and has a negative environmental impact. Regarding reminders, we have seen in previous research that the effect is not optimal. When sending a physical reminder letter to women who have not participated in more than 10 years (current routine), only 2% of the women invited came for sampling. Reminders with SMS are now standard for many businesses in society, such as car testing or dental appointments. It is inexpensive, saves the environment and there are studies that suggest it is more effective than sending physical letters. In this study, we intend to investigate whether SMS reminders, electronic letters, and physical letters for screening lead to increased participation and thus to a higher proportion of detected, treatable precursors of cervical cancer compared to before.",[26,27,28,29,30,31,32,33,34,35],"Cervical Cancer","Uterine Cervical Neoplasm","Uterine Neoplasms","Genital Neoplasm","Genital Neoplasm, Female","Uterine Diseases","Genital Diseases, Female","Neoplasms by Site","Neoplasms","Uterine Cervical Disease",[37,38,39],"participation","self sampling","screening","RECRUITING","2025-01-10",{"date":43,"type":44},"2025-01-14","ACTUAL",{"date":46,"type":44},"2019-08-19",{"date":48,"type":20},"2030-06-01",{"name":50,"class":51},"Karolinska Institutet","OTHER",6,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":15,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":5},"100475362","lymphedema-after-gyneco-oncologic-treatment-100475362","NCT05469945","Lymphedema After Gyneco-oncologic Treatment","Lower Limb Lymphedema After Gyneco-oncologic Therapy: Can we Prevent Irreversible Lymphedema?","Gynolymph","Inclusion Criteria:\n\n* Signed informed consent (ICF)\n* Female patient, recently diagnosed with gynaecologic cancer (cervix, endometrium, vulva, vagina, ovaries…) and candidate for curative treatment\n* Age ≥ 18 years\n* Understanding of the Dutch language\n* Able to understand the informed consent and willing to comply with the protocol, including use of diary or app and timely completion of requested questionnaires.\n\nExclusion Criteria:\n\n* History of treatment for gynaecologic cancer\n* Concurrent second primary tumor(s)\n* Pregnancy or pregnancy planned within 2 years\n* Known metastasized cancer at the time of inclusion (D0)\n* Severe injury, surgery or deformation of the legs or groins in the past\n* Vascular malformation of the leg or untreated venous insufficiency with oedema (CEAP C4 or more)\n* Mental or psychological problems, inability to comply to the study protocol\n* First treatment administered \\> 2 weeks before\n* Clinical signs and symptoms of lymphedema present (ISL stage 0 or higher) at the moment of intake","18 Years","99 Years",{"count":64,"type":20},218,[23],"Trial developed to inventory the incidence of early and advanced stage lower limb lymphedema in patients diagnosed with and treated for gynaecologic cancer.\n\nFour hundred patients with diagnosis stage 1-3 gynaecologic cancer will be included in an observational cohort between diagnosis until maximum 2 weeks after start of the first treatment. They will be followed for occurrence of lower limb lymphedema up till 2 years after their last treatment.\n\nData on signs and symptoms, quality of life, time investment and financial expenses will be collected, to provide information on the incidence and risk factors for lower limb lymphedema, and on its impact on patients, regarding quality of life, sexual well-being and time- and financial investment.\n\nPatients developing early stage LLL enter an interventional sub-cohort, in which the effect of class II compressive garments on preventing evolution towards advanced stage LLL will be evaluated.",[68,29],"Lymphedema",[70,71,72,73,74,75],"Lymphedema of the lower limb","Gynaecologic cancer","Sexual well-being","Quality of Life","Cost-investment","Time-investment","2024-06-17",{"date":78,"type":44},"2024-06-20",{"date":80,"type":44},"2022-06-22",{"date":82,"type":20},"2028-06-30",{"name":84,"class":51},"University Hospital, Ghent"]